🧪
hypothesis

Synergistic Timing With Acetylcholinesterase Inhibitors

Hypothesis

Synergistic Timing With Acetylcholinesterase Inhibitors

Scheduled 3mg melatonin 30 minutes after donepezil administration optimizes MT1/AChE-inhibitor cross-talk for amyloid and cholinergic pathway modulation.
🧬 MT1/MT2; AChE; CHRM1 (M1 muscarinic); BACE1🎯 Composite 52%💱 $0.61▲0.5%proposed
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates 9 support 4 oppose
✓ All Quality Gates Passed
Mechanistic 0.55 (15%) Evidence 0.38 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.515 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite52%

🧪 Overview

Scheduled 3mg melatonin 30 minutes after donepezil administration optimizes MT1/AChE-inhibitor cross-talk for amyloid and cholinergic pathway modulation. However, the synergistic mechanism is not established—cited studies show independent effects not interaction. Pharmacokinetic mismatch: donepezil Tmax is 3-5 hours while melatonin Tmax is 30-60 minutes, making the 30-minute interval rationale unjustified. AChE inhibitors represent 1990s technology as anti-amyloid antibodies become standard. One observational study showed no synergy. Commercial viability limited without novel combination formulation.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Donepezil<br/>Administration"]
    B["AChE Inhibition<br/>+ CHRM1 Activation"]
    C["MT1 / MT2<br/>Melatonin Receptor"]
    D["Scheduled Melatonin<br/>30 min Post-Donepezil"]
    E["Synergistic<br/>Cross-talk"]
    F["Amyloid Pathway<br/>Modulation"]
    G["Cholinergic<br/>Protection"]
    A --> B
    D --> C
    B --> E
    C --> E
    E --> F
    E --> G
    style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
    style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

⚖️ Evidence

⚖️ Evidence Matrix3 supports4 contradicts
Supports
Melatonin and AChE inhibitors show independent neuroprotective effects
PMID:21237503
Supports
MT1 receptor activation may potentiate muscarinic signaling
PMID:N/A
Supports
Combination approach addresses both amyloid and cholinergic pathways
PMID:25526817
Contradicts
MT1/AChE-inhibitor cross-talk mechanism not established in vivo
PMID:N/A
Contradicts
Donepezil Tmax 3-5h vs melatonin Tmax 30-60min makes 30-min interval pharmacologically irrational
PMID:N/A
Contradicts
Observational study showed no synergistic cognitive benefit
PMID:12591118
Contradicts
AChE inhibitor class declining as anti-amyloid antibodies become standard
PMID:N/A
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — MT1

No curated PDB or AlphaFold mapping for MT1 yet. Search RCSB →

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for MT1 →

No DepMap CRISPR Chronos data found for MT1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.1042
Events (7d)
1
Price History
▲0.5%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF donepezil 10mg + melatonin 3mg co-administered (30-minute interval) is compared to donepezil alone and melatonin alone in a 24-week trial, THEN the combination group will show statistically signifiCombination therapy will produce a superadditive effect on CSF Aβ42 levels and cognitive function, with interaction term p < 0.05 in mixed-effects model.— no observation —pending0.18
IF patients with Alzheimer's disease receive 3mg melatonin 30 minutes AFTER donepezil (optimized schedule) vs. simultaneous co-administration vs. 4 hours AFTER donepezil (aligned with donepezil Tmax),30-minute post-donepezil melatonin scheduling will produce ≥20% greater reduction in plasma Aβ42 compared to simultaneous or 4-hour delayed administration, demo— no observation —pending0.15
🔮 Falsifiable Predictions (2)
pendingconf 18%
IF donepezil 10mg + melatonin 3mg co-administered (30-minute interval) is compared to donepezil alone and melatonin alone in a 24-week trial, THEN the combination group will show statistically significant synergistic reduction in CSF Aβ42 (not merely additive) and ≥15% improvement inADAS-Cog score b
Predicted outcome: Combination therapy will produce a superadditive effect on CSF Aβ42 levels and cognitive function, with interaction term p < 0.05 in mixed-effects mod
Falsification: Combination effects equal exactly the sum of monotherapy effects (additive) or fall below the sum; interaction term in ANOVA not significant (p ≥ 0.05); or monotherapy-only groups show equal/superior
pendingconf 15%
IF patients with Alzheimer's disease receive 3mg melatonin 30 minutes AFTER donepezil (optimized schedule) vs. simultaneous co-administration vs. 4 hours AFTER donepezil (aligned with donepezil Tmax), THEN plasma Aβ42 concentration will decrease most significantly in the 30-minute interval group com
Predicted outcome: 30-minute post-donepezil melatonin scheduling will produce ≥20% greater reduction in plasma Aβ42 compared to simultaneous or 4-hour delayed administra
Falsification: No significant difference (p > 0.05) in plasma Aβ42 reduction between the 30-minute interval group and simultaneous or 4-hour delayed administration groups; or simultaneous/4-hour groups show numerica
View on SciDEX ↗